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Abstract 
Background: Lightheadedness, fatigue, weakness, heart palpitations, cognitive dysfunction, muscle pain, and 
exercise intolerance are some of the symptoms of orthostatic intolerance (OI). There is substantial comorbidity of OI 
in ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome). The 10-minute NASA Lean Test (NLT) is a simple, 
point-of-care method that can aid ME/CFS diagnosis and guide management and treatment of OI. The objective of 
this study was to understand the hemodynamic changes that occur in ME/CFS patients during the 10-minute NLT.
Methods: A total of 150 ME/CFS patients and 75 age, gender and race matched healthy controls (HCs) were enrolled. 
We recruited 75 ME/CFS patients who had been sick for less than 4 years (< 4 ME/CFS) and 75 ME/CFS patients sick for 
more than 10 years (> 10 ME/CFS). The 10-minute NLT involves measurement of blood pressure and heart rate while 
resting supine and every minute for 10 min while standing with shoulder-blades on the wall for a relaxed stance. 
Spontaneously reported symptoms are recorded during the test. ANOVA and regression analysis were used to test for 
differences and relationships in hemodynamics, symptoms and upright activity between groups.
Results: At least 5 min of the 10-minute NLT were required to detect hemodynamic changes. The < 4 ME/CFS group 
had significantly higher heart rate and abnormally narrowed pulse pressure compared to > 10 ME/CFS and HCs. 
The < 4 ME/CFS group experienced significantly more OI symptoms compared to > 10 ME/CFS and HCs. The circula-
tory decompensation observed in the < 4 ME/CFS group was not related to age or medication use.
Conclusions: Circulatory decompensation characterized by increased heart rate and abnormally narrow pulse 
pressure was identified in a subgroup of ME/CFS patients who have been sick for < 4 years. This suggests inadequate 
ventricular filling from low venous pressure. The 10-minute NLT can be used to diagnose and treat the circulatory 
decompensation in this newly recognized subgroup of ME/CFS patients. The > 10 ME/CFS group had less pronounced 
hemodynamic changes during the NLT possibly from adaptation and compensation that occurs over time. The 
10-minute NLT is a simple and clinically useful point-of-care method that can be used for early diagnosis of ME/CFS 
and help guide OI treatment.
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Background
Myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) is a debilitating disease with significant unmet 
medical needs that affects as many as 2.5 million people 
in the U.S. and causes enormous burden for patients, 
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symptoms of impaired function accompanied by severe 
fatigue, unrefreshing sleep, cognitive impairment and 
orthostatic intolerance are worsened by physical and cog-
nitive exertion causing post-exertional malaise (PEM) 
[1]. ME/CFS is generally considered to be a post-viral or 
post-infection syndrome with immune, metabolic and 
neurologic sequelae [2]. Between 84 and 91% of ME/CFS 
patients are not yet diagnosed [3]. At least one-quarter of 
ME/CFS patients are house- or bedbound at some point 
in their lives [4]. The economic impact of ME/CFS is 
$17–$24 billion annually for direct costs and $9.1 billion 
from lost household and labor force productivity [5, 6].
Orthostatic intolerance (OI) is defined as the devel-
opment of symptoms during upright posture that are 
relieved by lying down or reclining. Lightheadedness, 
headache, fatigue, weakness, heart palpitations, tremor 
and exercise intolerance are some symptoms of acute OI 
[7]. Chronic OI may present even more subtly with nau-
sea, neurocognitive deficits, sensitivity to heat, or sleep 
problems [8]. Various physiological irregularities and 
syndromes can underlie orthostatic symptoms includ-
ing postural orthostatic tachycardia syndrome (POTS), 
orthostatic hypotension (OH), neurally mediated hypo-
tension and each may have subgroups of their own (i.e. 
post-viral POTS, hyperadrenergic POTS, neurogenic 
orthostatic hypotension, etc.) [9].
While questions still exist concerning the exact role 
of OI in ME/CFS, increasing evidence shows substantial 
comorbidity. Indeed, the Institute of Medicine (IOM) 
published clinical diagnostic criteria for ME/CFS listing 
OI as one of the core features of the illness [1]. Head-up 
tilt table testing, and continuous heart rate monitoring 
are used in research of OI syndromes. However, nei-
ther of these modalities is readily available to clinicians 
or easily performed in the clinic. Standardized methods 
for point-of-care diagnosis and testing for ME/CFS are 
needed.
Simple yet promising bedside tools to acquire ortho-
static vital signs are standing or “leaning” tests (done 
with shoulders touching a wall for stability), wherein 
a patient’s heart rate (HR) and blood pressure (BP) are 
measured at set intervals before and after they move 
from a supine to standing position. Adoption of practical 
point-of-care tests for OI are important to improve ME/
CFS diagnosis, identify possible causes of OI, and direct 
treatment options.
Our aim was to determine the utility of the 10-min-
ute NLT as a point-of-care assessment of OI to aid in 
ME/CFS diagnosis and to gain an understanding of the 
hemodynamic changes associated with OI in ME/CFS. 
We found that the 10-minute NLT is easily adminis-
tered in the clinic and is useful for diagnosing hemody-
namic abnormalities that can be treated by physicians. 
Furthermore, use of the 10-minute NLT helped identify 
circulatory decompensation in a subgroup of ME/CFS 
patients. This is a newly recognized OI subgroup of ME/
CFS patients that can be diagnosed with the 10-minute 
NLT and treated appropriately.
Methods
Participants
150 ME/CFS patients who had been seen at Bateman 
Horne Center (Salt Lake City, UT) for routine clini-
cal care between February 2018 and September 2019 
and 75 matched HCs were recruited for the study. 
The 150 MECFS subjects included 75 sick with ME/
CFS for < 4  years (< 4 ME/CFS) and 75 sick for greater 
than 10  years (> 10 ME/CFS). The age range of ME/
CFS participants and HCs was 18–65  years at the time 
of informed consent. HCs were matched with < 4 ME/
CFS participants by age (± 5 years), gender and ethnicity. 
Enrolled ME/CFS participants were required to fulfill the 
International Chronic Fatigue Syndrome Study Group 
research criteria [10], the Canadian Consensus Criteria 
[11], and the IOM clinical diagnostic criteria [1]. HCs 
were recruited from the Salt Lake City metropolitan area 
using advertisements posted on social media, the clinic 
webpage or by phone contact with a volunteer pool from 
previous studies. HCs were considered generally healthy 
and between 18 and 65 years of age. HCs were excluded 
if they fulfilled ME/CFS diagnostic criteria or had a his-
tory of illness, had a BMI > 40 or had been treated with 
long-term (longer than 2  weeks) antiviral medication 
or immune modulatory medications within the past 
6 months or had been treated with short-term (less than 
2  weeks) antiviral or antibiotic medication within the 
past 30 days.
Baseline (Year 1) assessments
All research participants had a physical examination at 
the baseline visit in Year 1 that included evaluation of 
vital signs, body mass index (BMI), orthostatic vital signs, 
skin, lymphatic system, HEENT, pulmonary, cardiac, 
abdomen, musculoskeletal, nervous system and fibro-
myalgia (FM) tender points. Medical history and con-
comitant medications were documented. The 10-minute 
NLT was conducted following the physical examination. 
The 10-minute NLT is an orthostatic challenge stand-
ing lean test. It requires an exam table, a pulse oximeter 
placed on one hand and a blood pressure cuff placed on 
the opposite arm. Objective hemodynamic parameters 
(i.e. HR and BP) were recorded while subjects were rest-
ing supine for 10  min, then moved to a standing posi-
tion and remained standing for 10 min. Testing requires 
at least one person to scribe and monitor HR, signs, and 
symptoms and one person to obtain BP measurements. 
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Participants were first asked to lie down undisturbed for 
10 min. The participant was then asked to stand and lean 
against a wall with only shoulder blades touching and 
heels 6–8 inches from the wall. BP and HR are recorded 
every minute for 10 min and participants were asked to 
report any symptoms they experienced.
In addition, all subjects completed the following ques-
tionnaires before their baseline visit using REDCap, a 
secure and HIPAA compliant electronic data capture 
system; DePaul Symptom Questionnaire, Post-Exertional 
Fatigue Questionnaire, RAND-36, Fibromyalgia Impact 
Questionnaire-R, ACR 2010 Fibromyalgia Criteria Symp-
tom Questionnaire, Pittsburgh Sleep Quality Index, Stan-
ford Brief Activity Survey, Orthostatic Intolerance Daily 
Activity Scale, Orthostatic Intolerance Symptom Assess-
ment, Brief Wellness Survey, Hours of Upright Activity, 
medical history and family history.
Hemodynamic definitions
Systolic BP (SBP), diastolic BP (DBP) and HR were 
used as raw values recorded during the 10-minute NLT. 
Pulse pressure (PP) and narrowed pulse pressure (NPP) 
were calculated according to the consensus equation: 
PP = SBP- DBP and NPP = PP/SBP. PP is considered 
abnormally narrow if it is less than 25% of SBP [12]. Sub-
group analysis of < 4 and > 10 ME/CFS participants was 
conducted. For assessing OI manifestations, changes in 
HR and BP during the 10-minute NLT were classified as 
follows. OH was defined as a decrease in SBP of 20 mm 
Hg or more, or a decrease in DBP of 10 mm Hg or more 
in the first 3  min standing compared to resting supine 
values. POTS was defined as an increase of HR greater 
than 30 bpm or a HR of greater than 120 bpm, based on 
the average of the last three minutes standing. (e.g., if 
the standing portion of the test was terminated at 6 min, 
we calculated the mean of the data recorded during the 
3rd, 4th and 5th minutes). This allowed us to include 
results from participants unable to complete the 10-min-
ute NLT. OI symptoms were spontaneously reported by 
participants during the test. OI signs were observed and 
recorded by the scribe. We conceptualized OI symptoms 
by identifying and refining common words or concepts 
mentioned by participants. To assess the relationship 
between self-reported hours of upright activity (HUA) 
and hemodynamic changes during the 10-minute NLT, 
multiple linear regression was performed between the 
average values of hemodynamics data: SBP, DBP, HR, PP, 
and NPP in last 3  min standing. Also, additional multi-
ple logistic regression was performed for comparing 
hemodynamics between ME/CFS patients with < 5 HUA 
and > 5 HUA. HUA is defined as time spent with feet on 
the floor (sitting, standing, walking) in the last 24 h.
Statistical analysis
Data were analyzed by Excel and STATA/MP 13.1 Win-
dows [32-bit] version. All demographic data of subgroups 
were compared using ANOVA or T-test, where appropri-
ate. Repeated measures of ANOVA were used to detect 
differences in hemodynamic data of each subgroup in 
each minute and presented as Means (SD). Fisher’s Exact 
test was applied to demonstrate association between 
comprehensive hemodynamics trend results in each sub-
group. Descriptive statistics used for spontaneous OI 
symptom reports. The relationship between the hemody-
namic response and HUA was modeled by multiple linear 
regression after adjusting for age and gender. Effect mod-
ification by medication was evaluated via stratified analy-
ses and tested via the interaction term approach. Logistic 
regression was used to analyze HUA. T-test, F-test and 
Chi-Square test were used for validating models. A 
p-value of < 0.05 was considered statistically significant.
Results
Table  1 shows the baseline demographics and clinical 
characteristics of the study participants. The < 4 ME/CFS 
participants and HCs were similar in age and > 10 ME/
CFS participants were older (P < 0.005). The distribu-
tion of race and gender between the 3 groups was simi-
lar. The average HUA was 6.05 (SD ± 4.02) for all ME/
CFS participants. There was a significant difference in 
HUA between < 4 ME/CFS and > 10 ME/CFS participants 
(5.36 SD ± 3.65 compared to 6.75 SD ± 4.28, P < 0.05). The 
baseline HR was significantly different between all ME/
CFS participants and HCs (P < 0.0001) and between < 4 
ME/CFS and > 10 ME/CFS (P < 0.05). There was no differ-
ence in baseline supine SBP and DBP between groups.
We used the 10-minute NLT to evaluate hemodynamics 
in all 225 participants. The > 10 ME/CFS group showed a 
higher, increased trend of SBP compared to < 4 ME/CFS 
and HCs but the difference was not statistically signifi-
cant (P > 0.11, Fig. 1). All participants had a similar, sud-
den increase in DBP immediately after standing. The < 4 
and > 10 ME/CFS had significantly greater increases in 
DBP after 3 min compared to HCs (P > 0.05, Fig.  2). All 
participants had a sudden decrease in PP in the first 
minute of standing but there were no significant differ-
ences between groups. Abnormal NPP (PP/SBP < 25%) 
occurred in the < 4 ME/CFS group after 5 min (< 4 ME/
CFS 24.63% SD ± 7.71, > 10 ME/CFS 26.63% SD ± 7.85, 
HCs 27.47% SD ± 7.94, P > 0.11) and by 6 min the < 4 ME/
CFS have statistically significant NPP compared to the 
other groups  (F2,186 = 5.33, P > 0.006) (Fig.  3). Patients 
with ME/CFS demonstrated significant HR increases 
every minute compared to HCs even though all sub-
groups showed continuous HR increases as time standing 
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progressed (Fig.  4). The < 4 ME/CFS group had higher 
baseline HR compared to > 10 ME/CFS and HCs (< 4 ME/
CFS 73.55 SD ± 11.24, > 10 ME/CFS 68.9 SD ± 12.15, HCs 
62.64 SD ± 10.89,  F2,220 = 17.18, P > 0.00001) and signifi-
cantly higher HR compared to > 10 ME/CFS throughout 
the 10-minute NLT (P < 0.05). Spontaneous symptoms 
of muscle weakness, tingling, dizziness/lightheadedness 
and headache were more frequently reported by ME/
CFS patients while HCs reported headache, dizziness, 
light headedness, or nausea. Only one HC reported 
muscle weakness or tingling. Interestingly, presyncope 
and syncope occurred in 12% of HCs and 8% of both < 4 
and > 10 ME/CFS participants.   
The 10-minute NLT induced OI manifestations of 
POTS and OH in 54% of ME/CFS participants and 49% 
of HCs (Table 2). Further, HR increased in all groups for 
each minute of standing so that by 10 min 33% of HCs, 
42% < 4 MECFS and 38% > 10 MECFS met POTS crite-
ria. More ME/CFS participants spontaneously reported 
symptoms compared to HCs (P < 0.05). Even though the 
rate of POTS was similar among ME/CFS and HCs, sig-
nificantly fewer HCs reported OI symptoms (P < 0.005). 
Table 1 Participant characteristics
a P-Value < 0.0005
b P-Value < 0.005
c P-Value < 0.05
HCs (n = 75) ME/CFS (n = 150)  < 4 ME/CFS (n = 75)  > 10 ME/CFS (n = 75)
Age (SD) 38.5 (± 14)c 42.1 (± 13)c 39.0 (± 13)b 45.3 (± 12)b
Race % (n)
 White 97 (73) 98 (147) 99 (74) 97 (73)
 Other 3 (2) 2 (3) 1 (1) 3 (2)
Gender % (n)
 Male 28 (30) 40 (42) 31 (23) 25 (19)
 Female 72 (45) 60 (108) 69 (52) 75 (56)
HUA (SD) N/A 6.05 (± 4) 5.36 (± 4)c 6.75 (± 4)c
Supine vitals (SD)
 SBP 116.45 (± 15) 116.67 (± 15) 116.21 (± 14) 117.15 (± 15)
 DBP 75.54 (± 10) 76.73 (± 10) 76.89 (± 9) 76.57 (± 11)
 HR 62.64 (± 11)a 71.25 (± 12)a 73.55 (± 11)c 68.9 (± 12)c
Fig. 1 Systolic blood pressure (SBP) changes during the 10-minute NLT. Baseline blood pressure was measured while participants rested supine, 
then every minute upon standing for the 10-minute NLT. SBP was not significantly different between the three groups. However, the SBP for > 10 
ME/CFS patients was higher than < 4 ME/CFS and HCs and remained high for the duration of the 10-minute NLT
Page 5 of 9Lee et al. J Transl Med          (2020) 18:314  
Spontaneous OI symptom report in those without POTS 
or OH was greater in ME/CFS participants compared to 
HCs (P < 0.0005).
We determined whether hemodynamic changes dur-
ing the 10-minute NLT were due to medication. Similar 
results to those shown in Figs. 2 and 4 were found. ME/
CFS participants not taking medications had a signifi-
cantly higher baseline HR compared to HCs (P < 0.001). 
ME/CFS not taking prescription medications for OI had 
significantly different DBP (P < 0.009), HR (P < 0.001) and 
Fig. 2 Diastolic blood pressure (DBP) changes during the 10-minute NLT. Baseline blood pressure was measured while participants rested supine, 
then every minute upon standing for the 10-minute NLT. All participants had a similar, sudden increase in DBP immediately after standing. (Baseline 
DBP: < 4 ME/CFS 76.89 SD ± 8.89, > 10 ME/CFS 76.57 SD ± 10.56, HCs 75.54 SD ± 10.18; DBP after standing 1 min: < 4 ME/CFS 86.55 SD ± 10.69, > 10 
ME/CFS 84.11 SD ± 8.74, HCs 83.06 SD ± 10.38). DBP increased significantly for < 4 and > 10 ME/CFS after 3 min standing compared to HCs
Fig. 3 Change in pulse pressure during the 10-NLT. All participants had a sudden decrease in PP in the first minute after transitioning from lying 
down to standing. Abnormal NPP, defined as PP/SBP of < 25%, occurred in < 4 ME/CFS patients after 5 min (< 4 ME/CFS 24.63% SD ± 7.71, > 10 ME/
CFS 26.63% SD ± 7.85, HCs 27.47% SD ± 7.94, P > 0.11) and was significantly different from > 10 ME/CFS and HCs 6 min into the 10-minute NLT
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Fig. 4 Heart rate changes during the 10-minute NLT. Patients with ME/CFS demonstrated significant HR increases every minute compared to 
HCs even though the three groups showed continuous HR increases throughout the 10-minute NLT. Baseline HR and HR throughout the test was 
significantly higher for the < 4 ME/CFS group compared to > 10 ME/CFS and HCs
Table 2 OI manifestations during the 10-minute NLT
a P-Value < 0.0005
b P-Value < 0.005
c P-Value < 0.05
HCs (n = 75) (%) ME/CFS (n = 150) (%)  < 4 ME/CFS (n = 75) (%)  > 10 ME/CFS (n = 75) 
(%)
Hemodynamics
 POTS or OH any time sequence 49 54 60 48
 POTS or OH last 3 min standing 35 40 47 33
POTS
 1 min standing 15 15 12 19
 3 min standing 19 25 27 23
 5 min standing 23 28 31 26
 10 min standing 33 40 42 38
OH
 SBP decrease of 20 mm Hg or more 1 6 2 1
 DBP decrease of 10 mm Hg or more 0 1 1 0
OI symptoms
 OI symptoms reported 21a 55a 63c 48c
 OI symptoms PLUS signs 8b 25b 31 20
 OI signs ONLY 31 27 28 25
 OI symptoms ONLY 20a 50a 60 42
 POTS with symptoms 33 36 40 32
 OH with symptoms 1 3 5 1
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NPP (P < 0.04) during the last 3 min standing compared 
to HCs.
Logistic regression was used to determine whether HR 
was predictive of upright activity. A HR increase of 1 beat 
per minute resulted in 0.06 HUA decrease (P = 0.002). 
Therefore, we would predict HUA would decrease by 
1.8 h with a HR increase of 30 beats per minute. Indeed, 
HUA decreased 1.4 h in ME/CFS participants with POTS 
(P > 0.05, F = 0.17). HUA decreased 2.14 h in those ME/
CFS participants with POTS or OH plus spontaneously 
reported symptoms (P = 0.005, F = 0.03). However, hav-
ing POTS did not predict decreased HUA (P > 0.13, 
χ2 = 0.13).
Discussion
Our study demonstrated that the 10-minute NLT is a 
simple and meaningful point-of-care test that can be 
administered in a clinic setting by trained medical assis-
tants or nurses supervised by a clinician. We also showed 
that it takes at least 5 min of standing/leaning to detect 
meaningful hemodynamic changes and the full 10  min 
are likely to detect more. This is important because phy-
sicians generally do 1–3  min of standing in a routine 
orthostatic assessment. Van Campen et  al. have shown 
that abbreviated Tilt Table testing of only 2–5 min misses 
a substantial proportion of those ultimately diagnosed 
with POTS during a 10-min Tilt Table test [13]. Plash 
et  al. compared Tilt Test versus Standing hemodynam-
ics in POTS and state that while Tilt Testing produced 
larger increases in heart rate, both Tilt and Stand tests 
done for 10 min provide meaningful data [14]. Sensitivity 
of the 30 bpm criterion was similar for both tests (TILT-
10 = 93%, STAND10 = 87%), but Specificity was less at 
10 min for TILT (40%) than 10 min STAND (67%). They 
caution that a diagnosis of POTS should include other 
OI criteria and not be based solely on increases in heart 
rate regardless of test used. It is important to emphasize 
that Tilt Table testing is not readily available to all ME/
CFS patients, and protocols and interpretation of results 
differ from center to center. That is why an in-office 
10-minute NLT is important. We propose that the objec-
tive measurements obtained from the 10-minute NLT are 
clinically useful in symptomatic patients regardless of the 
cause and provide direction for supportive care. While 
it is likely that chronic OI in ME/CFS is compounded by 
severe deconditioning, this cannot be the only cause, as 
many experience OI from the early onset of disease, even 
if fit and active at the time they become ill.
The high occurrence of syncope and increased heart 
rate of > 30 bpm in HCs during the 10-minute NLT was 
not anticipated but is not surprising. The 10-minute NLT 
very effectively removes the “muscle pump” leaving only 
the neurovascular response to the completely vertical 
orthostatic stress (that is leaning for 10 min). It is note-
worthy that many “healthy” people experience syncope 
during head up tilt table testing [15] and tilt table tests are 
performed at a 70% angle whereas the 10-minute NLT is 
totally vertical. A HR increase of > 30 during the 10-min-
ute NLT was the most common orthostatic change in 
vital signs for all subjects. One explanation might be that 
all study participants were required to arrive fasting for a 
blood draw done about 30 min before the 10-minute NLT 
and might explain increased rates across all groups (fast-
ing glucose levels were similar among groups, data not 
shown). It is important to emphasize, however, that spon-
taneous reporting of OI symptoms during the 10-minute 
NLT was much more common and diverse in the ME/
CFS patients than HC.
OI is a common chronic complaint in the ME/CFS 
population that only occasionally occurs in otherwise 
healthy people (usually an acute problem triggered by 
heat, dehydration or emotional triggers that are easily 
remedied). One clear indicator of the chronic pervasive 
nature of OI in ME/CFS is self-reported HUA. Although 
HUA data were not collected in healthy controls, one can 
estimate at least 12–15 HUA on average in healthy indi-
viduals. In this study the average HUA for all ME/CFS 
participants was 6 h per 24-h period. The combination of 
OI symptoms induced by upright posture with low HUA 
in ME/CFS strongly support an underlying chronic dis-
order of OI. In addition, our study also demonstrates that 
the underpinnings of OI in ME/CFS are more complex 
than just meeting criteria for POTS.
Higher heart rates (both resting and standing) and 
a pathologic drop in pulse pressure stand out as distin-
guishing markers of illness between the ME/CFS and 
HCs. Almost every measured response (other than syn-
cope or presyncope) to orthostatic stress was most dra-
matic in the < 4 ME/CFS, followed by > 10 ME/CFS and 
the least in HC. Blood pressure and heart rate variabil-
ity have been proposed as potential biomarkers of ME/
CFS. Frith et al. [16] used tilt table testing and identified 
blood pressure variability in ME/CFS and proposed it as 
a bedside diagnostic tool to measure abnormal hemody-
namics. A study that used a 20-min standing test identi-
fied heart rate variability as a potential marker of fatigue 
in ME/CFS with POTS [17]. The ME/CFS POTS patients 
in this study had a shorter duration of illness (average 
6  years) compared to the ME/CFS only group (average 
10  years). Finally, Richardson et  al. [18] used the same 
20-min standing test but without hemodynamic assess-
ment and detected an increase in Activin B in ME/CFS 
but not in healthy controls in response to the orthostatic 
challenge that correlated with ME/CFS disease severity. 
This pattern suggests that those with longstanding ME/
CFS illness have adapted to their condition in some ways.
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The striking finding of abnormally narrowed pulse 
pressure in the < 4 ME/CFS group suggests a signifi-
cant drop in ventricular stroke volume while standing 
in place that can only be explained by a relative hypov-
olemia. Typical causes of an abnormally narrowed pulse 
pressure are constrictive (cardiac tamponade or restric-
tive pericarditis), outflow obstruction (aortic or pulmo-
nary stenosis), pump failure from a diseased heart, or 
shock (anaphylactic, septic, cardiogenic) [12] and none of 
these are present in the ME/CFS patients enrolled in this 
study. The pressing research question raised by this study 
is what is causing the problem. Small studies that have 
not yet been replicated suggest autoantibodies against 
adrenergic and muscarinic receptors [19], or a neuroin-
flammatory process [20] may be playing a role. Invasive 
cardiopulmonary exercise test (iCPET) was used to show 
that ME/CFS patients have reduced atrial filling pres-
sures and impaired systemic oxygen extraction during 
exercise compared to healthy people. This may be related 
to abnormal delivery of oxygen due to microscopic left to 
right shunt at the tissue level, and/or abnormal cellular 
uptake of oxygen [21]. We hypothesize that patients with 
ME/CFS have lower tolerance of the perfusion changes 
induced by orthostatic stress, from autonomic nervous 
system dysregulation in combination with abnormal cel-
lular energy metabolism.
While it isn’t entirely clear why the > 10 ME/CFS group 
appear to tolerate the orthostatic stress better than < 4 
ME/CFS in terms of a dramatic drop in pulse pressure, 
that does not prove they aren’t experiencing a drop in 
cerebral perfusion. It is possible that after many years 
of ME/CFS illness there is gradual adaptation of the cir-
culatory stress response to upright posture. That may 
also explain why the > 10 ME/CFS had the highest rise 
in SBP during the 10-minute NLT. There is also an age 
difference between the < 4 and > 10 ME/CFS groups of 
about 5–6 years which might also explain the higher SBP 
response in the > 10 ME/CFS subgroup. A very impor-
tant recently published study demonstrated that cerebral 
blood flow is reduced in ME/CFS during head-up tilt 
testing even in the absence of hypotension or tachycardia 
[22]. This is consistent with our findings and may explain 
why ME/CFS patients were not much more likely to meet 
standard criteria for POTS or OH than the HCs, even 
though they still became more symptomatic during the 
10-minute NLT.
This study has limitations. The study originally aimed 
to recruit 150 ME/CFS patients sick for < 4  years and 
was amended after 1  year to recruit 75 < 4 and 75 > 10 
ME/CFS for comparison. By this time the HCs had been 
recruited and matched with the < 4  year ME/CFS. This 
is why the > 10 ME/CFS group is older and not matched 
with HCs. Participants were not required to taper off all 
medications in advance of the 10-minute NLT, although 
many did not take their morning medications due to 
fasting for the blood draw. This should potentially have 
blunted the response to the 10-minute NLT making 
the problem look less severe, or conversely, by skipping 
morning meds and fasting, may have caused rebound 
symptoms making the results look worse. It is unclear 
why ME/CFS on OI medications had more severe OI 
findings, but it’s possible that more severe underlying OI 
led to the use of these medications as well as a more dra-
matic response to withholding meds for the fasting blood 
draw.
Conclusion
In conclusion, the use of the point-of-care 10-minute 
NLT identified circulatory decompensation in a subgroup 
of ME/CFS patients sick for < 4  years. The 10-minute 
NLT is a simple, in-office assessment that can be used for 
early diagnosis and management of ME/CFS. The most 
important take-home clinical message from this study is 
that the identification of OI in ME/CFS will immediately 
provide information for objectively supported diagnoses 
and evidence-based targeted treatment, drawing from a 
large literature regarding OI and POTS, even if the cause 
is unknown.
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